Wall Street analysts expect Teladoc, Inc. (NYSE:TDOC) to report earnings per share (EPS) of ($0.50) for the current quarter, Zacks Investment Research reports. Thirteen analysts have issued estimates for Teladoc’s earnings, with estimates ranging from ($0.58) to ($0.22). Teladoc posted earnings per share of ($0.33) in the same quarter last year, which indicates a negative year-over-year growth rate of 51.5%. The company is expected to issue its next earnings report after the market closes on Wednesday, November 1st.
On average, analysts expect that Teladoc will report full year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.63) to ($0.94). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.72) to ($0.35). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Teladoc.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm had revenue of $44.60 million for the quarter, compared to analysts’ expectations of $44.39 million. During the same quarter in the prior year, the business posted ($0.38) earnings per share. Teladoc’s revenue was up 68.3% on a year-over-year basis.
Several research firms recently commented on TDOC. BidaskClub raised shares of Teladoc from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Teladoc in a research report on Friday, July 28th. KeyCorp reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Teladoc in a research report on Sunday, September 17th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Teladoc in a research report on Tuesday, September 26th. Finally, Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $38.00.
In other Teladoc news, VP Mark Hirschhorn sold 25,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $31.93, for a total transaction of $798,250.00. Following the sale, the vice president now directly owns 64,987 shares of the company’s stock, valued at approximately $2,075,034.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now directly owns 33,008 shares in the company, valued at $1,020,607.36. The disclosure for this sale can be found here. Insiders have sold a total of 168,806 shares of company stock worth $5,430,382 over the last three months. Insiders own 4.47% of the company’s stock.
Several hedge funds have recently modified their holdings of TDOC. ETF Managers Group LLC bought a new stake in shares of Teladoc in the 2nd quarter valued at about $104,000. Great West Life Assurance Co. Can bought a new stake in shares of Teladoc in the 1st quarter valued at about $105,000. US Bancorp DE raised its holdings in shares of Teladoc by 10.3% in the 1st quarter. US Bancorp DE now owns 4,617 shares of the health services provider’s stock valued at $116,000 after purchasing an additional 433 shares during the period. Bank of Montreal Can raised its holdings in shares of Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the period. Finally, Pacad Investment Ltd. bought a new stake in shares of Teladoc in the 2nd quarter valued at about $135,000. 94.41% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “-$0.50 EPS Expected for Teladoc, Inc. (TDOC) This Quarter” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/10/21/0-50-eps-expected-for-teladoc-inc-tdoc-this-quarter.html.
Shares of Teladoc (TDOC) traded up 0.59% during mid-day trading on Monday, hitting $34.25. The company had a trading volume of 608,687 shares. The firm’s 50-day moving average price is $33.33 and its 200 day moving average price is $33.33. The company’s market capitalization is $1.94 billion. Teladoc has a one year low of $14.00 and a one year high of $37.55.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.